EGFR and non-small cell lung carcinoma: Most recently, AstraZeneca reported on the preclinical development and validation of AZD3759, a brain penetrating orally active EGFR inhibitor currently undergoing a phase I clinical trial in patients with mutation positive NSCLC [62,65].